Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 2
2012 1
2013 3
2014 3
2015 4
2017 1
2018 3
2019 1
2020 5
2021 1
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Inflammatory Mechanisms of HCC Development.
Refolo MG, Messa C, Guerra V, Carr BI, D'Alessandro R. Refolo MG, et al. Cancers (Basel). 2020 Mar 10;12(3):641. doi: 10.3390/cancers12030641. Cancers (Basel). 2020. PMID: 32164265 Free PMC article. Review.
Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions.
Notarnicola M, Osella AR, Caruso MG, Pesole PL, Lippolis A, Tutino V, Bonfiglio C, De Nunzio V, Scavo MP, Mirizzi A, Franco I, Lippolis T, D'Alessandro R, Refolo MG, Messa C. Notarnicola M, et al. Among authors: refolo mg. Int J Mol Sci. 2021 Apr 9;22(8):3899. doi: 10.3390/ijms22083899. Int J Mol Sci. 2021. PMID: 33918878 Free PMC article. Review.
The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines.
Schirizzi A, Contino M, Carrieri L, Riganti C, De Leonardis G, Scavo MP, Perrone MG, Miciaccia M, Kopecka J, Refolo MG, Lotesoriere C, Depalo N, Rizzi F, Giannelli G, Messa C, D'Alessandro R. Schirizzi A, et al. Among authors: refolo mg. Front Oncol. 2023 Feb 16;13:1129832. doi: 10.3389/fonc.2023.1129832. eCollection 2023. Front Oncol. 2023. PMID: 36874116 Free PMC article.
Reversibility of regorafenib effects in hepatocellular carcinoma cells.
D'Alessandro R, Refolo MG, Lippolis C, Messa C, Cavallini A, Rossi R, Resta L, Di Carlo A, Carr BI. D'Alessandro R, et al. Among authors: refolo mg. Cancer Chemother Pharmacol. 2013 Oct;72(4):869-77. doi: 10.1007/s00280-013-2269-8. Cancer Chemother Pharmacol. 2013. PMID: 23959464 Free PMC article.
VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment.
Schirizzi A, Arshadi A, Tolomeo D, Schirosi L, Valentini AM, De Leonardis G, Refolo MG, Donghia R, Storlazzi CT, Zito A, Ricci AD, Vallarelli S, Ostuni C, Bencivenga M, De Manzoni G, Messa C, Armentano R, Giannelli G, Lotesoriere C, D'Alessandro R. Schirizzi A, et al. Among authors: refolo mg. Biomedicines. 2023 Oct 7;11(10):2721. doi: 10.3390/biomedicines11102721. Biomedicines. 2023. PMID: 37893095 Free PMC article.
The role of miRNA-133b and its target gene SIRT1 in FAP-derived desmoid tumor.
Rotelli MT, Refolo MG, Lippolis C, Cavallini A, Picciariello A, Piscitelli D, Altomare DF. Rotelli MT, et al. Among authors: refolo mg. Oncotarget. 2020 Jun 30;11(26):2484-2492. doi: 10.18632/oncotarget.27622. eCollection 2020 Jun 30. Oncotarget. 2020. PMID: 32655835 Free PMC article.
31 results